MKI67 Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant MKI67.
- CITATIONS: 2
|Application ||WB, IF, E|
|Calculated MW||358694 Da|
|Other Names||Antigen KI-67, MKI67|
|Target/Specificity||MKI67 (NP_002408, 3157 a.a. ~ 3256 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||MKI67 Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
Provided below are standard protocols that you may find useful for product applications.
This gene encodes a nuclear protein that is associated with and may be necessary for cellular proliferation. Alternatively spliced transcript variants have been described. A related pseudogene exists on chromosome X.
Evaluation of candidate stromal epithelial cross-talk genes identifies association between risk of serous ovarian cancer and TERT, a cancer susceptibility hot-spot. Johnatty SE, et al. PLoS Genet, 2010 Jul 8. PMID 20628624. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. Zhao P, et al. BMC Cancer, 2010 May 20. PMID 20487522. Immunohistochemical overexpression of the p53 protein and Ki-67 (MIB-1) antigen in patients with GERD and chronic esophagitis. Binato M, et al. Appl Immunohistochem Mol Morphol, 2010 May. PMID 20414055. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. Ladstein RG, et al. BMC Cancer, 2010 Apr 14. PMID 20398247. CD147 expression in pituitary adenomas and its significance for clinical outcome. Qu X, et al. Hum Pathol, 2010 Aug. PMID 20381119.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.